Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01111292 · ClinicalTrials.gov registry record · Phase 1
Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01111292: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01111292 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01111292, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This pilot, randomized phase I/II trial studies how well inositol works in preventing colorectal cancer in patients with abnormal cells (dysplasia) associated with inflammation of the colon (colitis). Patients with colitis-associated dysplasia may have an increased risk of developing colorectal cancer. Inositol is a vitamin-like substance that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Placebo
- DRUG Inositol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01111292
The ClinicalTrials.gov registry entry for NCT01111292 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01111292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01111292 about?
NCT01111292 is a clinical study titled "Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia". This pilot, randomized phase I/II trial studies how well inositol works in preventing colorectal cancer in patients with abnormal cells (dysplasia) associated with inflammation of the colon (colitis). Patients with colitis-associated dysplasia may have an increased risk of developing colorectal canc...
What is the current status of trial NCT01111292?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2010-10. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01111292?
The interventions under investigation include: Placebo (OTHER), Inositol (DRUG).
Who is sponsoring clinical trial NCT01111292?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.